
Description
Factor XIII (A subunit) Polyclonal Antibody – HRP Conjugated
Affinity’s Factor XIII (A subunit) Polyclonal Antibody – HRP Conjugated is the base level of our horseradish peroxidase conjugated Factor XIII (A subunit) antibodies. The purity of IgG is typically 90% and is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v). The titre is essentially the same as the starting antiserum and each vial typically contains the amount of IgG recovered from one milliliter of antiserum however this IgG has been conjugated with Horseradish Peroxidase as an enzyme reporter. This Factor XIII (A subunit) Polyclonal Antibody – HRP Conjugated is generally intended for use as labeled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAF13A-HRP
Retail Product Size: 0.2mg vial
Host Animal: Sheep Anti-Human Factor XIII (A subunit) Polyclonal Antibody – HRP Conjugated
Species Cross Reactivity: View Chart
Product Datasheet: Factor XIII F13 Subunit A Polyclonal Antibody, hrp conjugated anti-human sheep IgG
Description of Factor XIII (FXIII)
Factor XIII (FXIII, fibrin stabilizing factor) is the proenzyme form of a transamidase that is essential for normal haemostasis and fibrinolysis, wound healing, female fertility and foetal development. Extracellular F.XIII consists of A subunits (83 kDa each) which contain the enzyme moiety, and B subunits (76 kDa each) which act as a carrier protein for the A subunit in circulation. Both subunits are produced under separate genetic control. In plasma, FXIII exists as a non-covalent tetrameric complex (320 kDa) of two A-subunits and two B-subunits (A2B2). The concentration of F.XIII tetramer in plasma is ~25 μg/ml (~80 nM). An intracellular form of FXIII is found in platelets, megakaryocytes and monocytes. This form of F.XIII presents as a dimer of two A-subunits only and has a molecular weight of 160 kDa. The importance of these intracellular stores is demonstrated by the observation that platelets can contribute up to half of the FXIII activity in platelet rich plasma. The activation of FXIII involves several steps. Thrombin cleaves after Arg37 of each A-subunit in the A2B2 tetramer, releasing a 4.5 kDa activation peptide. Additional conformational changes induced by the binding of calcium, and by dissociation of the B-subunits from the A-subunit dimer are required to obtain full enzyme activity. FXIIIa is a cysteine protease that catalyses the formation of γ-glutamyl-ε-lysyl bonds between the γ and α chains of polymerised fibrin molecules. Other proteins found crosslinked into fibrin clots by FXIIIa include fibrinogen, α2antiplasmin, fibronectin, vitronectin and von Willebrand factor 1-3.
References and Review
- McDonagh J; Structure and Function of Factor XIII; in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp 301-313, J.B. Lippincott Co., Philadelphia PA, USA, 1994.
- Inbal A, Muszbek L; Coagulation Factor Deficiencies and Pregnancy Loss; Seminars in Thrombosis and Haemostasis 29, pp 171-174, 2003.
- Murdock PJ, Owens DL, Chitolie A, Hutton RA, Lee CA; Development and Evaluation of ELISAs for Factor XIIIA and XIIIB Subunits in Plasma; Thrombosis Research 67, pp 73-79, 1992.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
重组HMGB1A盒蛋白,一种HMGB1拮抗剂,由pQE-80L/DHFR/HMGB1Abox载体转染大肠杆菌,再经处理纯化获得。
有无公司代做的?
2、抗HMGB1中和抗体
在一篇文献中看到一种chickenanti-pigHMGB1polyclonalantibody,没有公司和货号。
文献《Contributionsofhighmobilitygroupboxproteininexperimentalandclinicalacutelunginjury》
两种都可以,急求!万分感谢!
海正药业致力于研发多个单克隆抗体药物,其中第一个单克隆抗体药物安佰诺有望2014年获批上市,此次批准临床的重组人-鼠嵌合抗CD20单克隆抗体注射液,将为海正药业的单抗事业添砖加瓦。同时,海正药业已于2013年11月申报重磅药阿达木单抗(修美乐)的临床申请,单抗药物行业进入壁垒高,临床治疗效果显著,具有极其广阔的市场前景,容易诞生重磅炸弹级产品 。
希望可以帮到你,望采纳
分子式:C6428H9976N1720O2018S42 (仅多肽部分)
分子量:144 985 Da (仅多肽部分)
辅料包括:蔗糖、聚山梨酯80、十二水合磷酸氢二钠、二水合磷酸二氢钠和注射用水。
【性状】:澄清至半透明的无色至淡黄色液体。
参考资料:http://baike.baidu.com/view/10489361.htm
详细原因细胞生物学产品专家齐氏生物整理如下:
目前,多种表达系统均可实现重组抗体的异源表达,但是抗体药物的产业化制备,始终以动物细胞大规模培养工艺为主。1986年首个治疗性抗体OKT3TM上市之初,动物细胞表达水平普遍不足100mg/L。经过近三十年间发展,业内用于重组抗体生产的动物细胞培养工艺,无论细胞培养密度,还是抗体表达水平均提高五十倍以上。流加培养工艺中细胞密度可达1~2×107 cell/mL,日均产量200mg/L/day以上(最高可达700mg/L/D),最终收液的容积产率可达3-5g/L(最高达13g/L),培养体积可至20,000L(Lonza, Portsmouth/NH—facility);灌注培养工艺中细胞密度可达2×108cell/ml,抗体容积产率最高达25~40g/L(Percivia公司XD?灌注系统)。以上行业技术水平的飞速提升,既源于上游细胞系构建技术的突破,也得益于细胞大规模培养工艺的日臻成熟。尤其是后者综合培养基开发,工艺优化,结合新型生物反应器的使用,实现了动物细胞的高密度、高表达培养,满足了临床上对于抗体药物“公斤级”产能的需求。
动物细胞的体外培养,涉及生物反应器的物理参数(温度、pH、DO、DCO2等)、培养基的营养成分(葡萄糖、谷氨酰胺、氨基酸、维生素等)的消耗,以及自身代谢产物(乳酸、氨、重组蛋白等)的积累与生理生化参数(细胞密度、活性,能荷等)的变化。作为重组抗体生产的“细胞工厂”,上述过程参数的改变会直接影响生产细胞系的活性与重组抗体的收率。比如:当乳酸(58 mM)、渗透压(382 mOsm/kg)、氨(5.1 mM)参数超过其相应的阈值,细胞活性和抗体产量均会明显下降。目前,业内已经对于细胞培养过程参数进行了深入的研究,在动物细胞大规模培养中下述参数的控制也已成定式
随着组学技术的发展与应用,目前的细胞培养工艺开发,已经从简单的工艺参数优化,进入系统的组学研究深度,生产细胞的代谢网络与重组抗体合成机制日益清晰。对于生产细胞系在不同工艺条件下抗体产量的差异,已经能够从基因组、蛋白组、代谢组等不同层次进行分析、解释。这就为今后大规模细胞培养工艺开发提供了新的线索。同时,业内随着“QbD”理念的深入,越来越多的“过程分析技术”(Process analytical technologies)开始应用于细胞培养过程,旨在通过加强关键过程参数的监控来确保蛋白药物的最终质量。如:培养基检测、培养过程监控、多批次数据分析等。未来基于重组抗体表达的细胞大规模培养工艺开发,将朝着稳定产能,提高质量的方向发展。

